Report Overview
Advanced medical wearables now comprise smart patches, smart rings, smart garments and smart ear buds and the emergence of validated medical-grade technology in consumer devices is seen as critical in delivering the next generation of wearables. Regulators are supportive and payers are seeing the contribution wearables can make to lowering the overall cost of health.
So, how can pharma benefit? In Innovations in Wearables for Digital Health digital health experts review the current wearables sector, examine the technologies that will shape the future and identify the challenges and areas of opportunity for pharma.
Key Therapies Covered
Bavencio (avelumab)
Keytruda (pembrolizumab)
Opdivo (nivolumab)
Tecentriq (atezolizumab)
Imfinzi (durvalumab)
Cabometyx (cabozantinib)
Fotivda (tivozanib)
Inlyta (axitinib)
Lenvima/Kisplyx (lenvatinib)
Sutent (sunitinib)
Votrient (pazopanib)
Afinitor (everolimus)
abexinostat
MK-6482
bempegaldesleukin
Content Highlights
- Subject synopsis
- Research methodology and objectives
- Key insights summary
- Issues and insights
What Our Clients Are Saying
“Excellent”
Director, Medical Affairs, AstraZeneca
“...this report has been very valuable”
Director, Biotech New Product Planning and Drug Delivery, Eli Lilly
Access The Report
Please complete the form below to download
FirstWord Perspectives - Digital Opinion Leaders: Engagement Strategies for Pharma
© 2022 FirstWord. All rights reserved | 1140 Avenue of the Americas, 14th Floor, New York, NY 10036
Partial List of Participating KOLs
Deputy Director
Georgetown Lombardi Comprehensive Cancer Center, and the Scholl Professor and vice chair of the Department of Medical Oncology at Georgetown University Medical Center, Georgetown University School of Medicine, Washington, DC
Associate Professor of Oncology
Roswell Park Comprehensive Cancer Center, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY
Professor
Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Head of the Medical Oncology Department
Hospital Universitario Central de Asturias, Oviedo, Spain
Professor of Medicine
Head of the SS Genitourinary Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Professor of Oncology and Chief of the Oncology
Clinical and Translational Research Unit at Georges Pompidou Hospital, Paris, France
Our Research
We engage the world’s leading key opinion leaders, ensuring the viewpoints delivered are authoritative and consequential. Strict screening criteria ensures high-quality interviews.
Our in-house senior analysts and medics leverage their disease area knowledge and market research expertise to identify the key questions and issues.
Our reports provide a detailed analysis, based on the candid views of world-renowned KOLs, of how treatment algorithms are likely to evolve over the next 3-5 years.
View A Full List Of Therapy Trends Reports
Leading KOLS
KOL Answers
Future Focused
Expert Contributors
- Paying for Value
- Building on success of value-based approaches in health care
- Drug VBCs are a priority for some payers
- Choosing the right products
- Manufacturer competence needed for VBC
- Choosing the right payer to work with on a VBC
- VBCs can be offered at launch
- Technology is enabling VBCs
- Piloting VBCs
- Choosing the VBCs to publicize
- The challenges in scaling up use of VBCs
Each issue addressed is broken down into the following subsections
- Issue summary
- Questions
- Key insights
- Expert quotes
- Intelligence exhibits
- Executive level experience in digital health, digital patient services or digital patient support with at least five years of involvement in digital health initiatives.
- At least three years’ experience in the field of digital health, mobile health, or digital capabilities for health.
- Direct experience designing, executing or influencing innovations in wearables for digital health initiatives in the last 18 months.
- Joel Beilin, Founder and CEO of Global Audiology Consulting, Denmark
- Giovanni Di Sarro, Senior Business Partner of Global Digital Solutions at Lundbeck, Denmark
- Pierre-Alexandre Fournier, Co-founder of Hexoskin, a leading sensor and AI/analytics company for health, research and medicine
- Serkan Oray, Vice President of Devices, Packaging, & Wearable Technologies at UCB, Belgium
- Panos Papakonstantinou, Global Commercial Director of Mobility Solutions at the Novartis Institutes for BioMedical Research (NIBR), Switzerland
- Gergely Vértes, Solution Accelerator Lead and the Wearable Clinical Project Lead in Epilepsy at UCB Bekgium
- Dr. Jian Yang, Senior Director of Digital Health at Eli Lilly and Company, US
- Anonymous, technology leader, multinational biopharmaceutical company
DIGITAL HEALTH INTELLIGENCE REPORT COLLECTION
Digital Opinion Leaders: Engagement Strategies for Pharma
Digital Opinion Leaders (DOLs) have significant influence across digital channels and can provide a wide-range of dynamic content on social media platforms such as YouTube, Twitter, or Facebook. Their much broader global audience offers pharma considerable HCP and patient engagement opportunity, but, unlike KOLs, the experience, knowledge and motivation of DOLS cannot be assured. How can pharma safely work with this expanding group of online health influencers?
Digital Opinion Leaders: Engagement Strategies for Pharma draws on primary source research and the experience of experts to examine the practical challenges of identifying, recruiting and engaging DOLs in pharma’s business.
IQVIA’s AI-driven Pipeline Architect brings the commercial future into sharper focus during clinical trials, so you can streamline your development process and prioritize the most promising compounds.
Lorem ipsum dolor sit amet
By completing the form above, you agree to subscribe to FirstWord Pharma and receive our marketing offers in accordance with our Privacy Policy
RxY is a multi-client service that delivers the Real Reasons Behind Prescribing Decisions.
RxY’s mission is to help client brands grow patient share through quantifying the “Real Reasons” behind prescribing decisions for “in-play/dynamic” patients, helping brand teams to maximize critical commercial opportunities.
The RxY team is composed of relevant therapy experts who deploy knowledge to ensure you get the most out of the RxY data in order to develop commercial or medical strategies that have real-world applications.
Learn more or contact us today
This report has been sponsored by RxY